NCT06021626

A Study of CRD3874-SI in People With Solid Tumors

A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants. After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for for patients with advanced or metastatic malignant solid tumors including sarcoma and Merkel Cell Carcinoma.

Conditions

• Sarcoma
• Merkel Cell Carcinoma

Interventions

Type	Name	Description
DRUG	CRD3874	Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI. Cohort CRD3874-SI Dose level (mg/kg) 1. 0.1 2. 0.3 3. 0.9 4. 1.8 5. 2.7 6. 4.05

Timeline

• Start date: 2023-08-25
• Primary completion: 2029-08-01
• Completion: 2029-08-01
• First posted: 2023-09-01
• Last updated: 2025-12-19

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study